查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1862809

G蛋白偶联受体市场按受体类别、治疗领域、应用和最终用户划分－2025-2032年全球预测

G-Protein Coupled Receptors Market by Receptor Class, Therapeutic Area, Application, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，G 蛋白偶联受体市场将成长至 58 亿美元，复合年增长率为 6.46%。

关键市场统计数据
基准年 2024 35.1亿美元
预计年份：2025年 37.4亿美元
预测年份 2032 58亿美元
复合年增长率 (%) 6.46%

本书清晰权威地介绍了G蛋白偶联受体（GPCR）的科学原理和商业化应用，并将近期技术突破置于治疗和转化应用的背景下进行阐述。

G蛋白偶联受体（GPCR）在细胞讯号传导和治疗创新中占据核心地位，是药理学上最容易研究的膜蛋白家族之一。过去二十年来，高解析度结构生物学、冷冻电镜和整合计算建模等技术的进步，大大提升了我们分析受体构象、配体结合模式和讯号传导偏差的能力。这些科学突破催生了种类繁多的小分子、胜肽类、生物製药以及靶向以往难以研究的受体亚型的、不局限于特定给药途径的药物研发平台。

此外，从化学蛋白质体学到先进成像技术和人类细胞模型等转化工具的成熟，加强了标靶检验与临床开发之间的关联。因此，製药、生物技术、学术界和受託研究机构（CRO）等产业的相关人员都在优先考虑那些具有差异化疗效、更佳安全性以及全新作用机制的G蛋白偶联受体（GPCR）产品组合。这促使相关人员重新评估其投资策略、共同研究模式和市场推广策略，以掌握涵盖传统治疗领域和新兴适应症的各种机会。

结构生物学、计算设计和模式创新如何融合，正在重新定义GPCR标靶药物发现，并重塑整个产业的合作模式

在科学、技术和经营模式创新融合的驱动下，GPCR领域正经历变革性的转变。结构测定方法，特别是冷冻电镜和先进的X射线晶体衍射技术，能够提供GPCR-配体复合物的高分辨率图像，从而加速基于结构的先导化合物设计和合理的先导化合物优化。同时，对偏向性激动作用和变构调节的深入理解正在拓展治疗药物的设计空间，使下游讯号路径的调控更具选择性，并有可能减少脱靶效应。

同时，人工智慧和机器学习在配体设计和虚拟筛检工作流程中的应用，提高了先导化合物的发现效率，并实现了对化学空间的快速探索。此外，胜肽类药物、基于抗体的GPCR标靶化以及细胞内递送策略等多种治疗方式的多样化，拓展了选择性结合受体的途径。在商业性，这些技术变革正在推动生物技术公司与大型製药公司之间建立新的合作模式，促进与拥有专有测试平台和患者衍生模型的专业受託研究机构和学术机构进行垂直合作。随着这些趋势的持续发展，那些能够将深刻的机制理解与敏捷的转换能力结合的机构将日益获得竞争优势。

评估关税驱动的供应链调整与采购变化如何重塑各相关利益者群体的GPCR研发营运策略

2025年美国关税相关政策的变化已对GPCR研发相关的供应链、成本结构和筹资策略产生了波动。这种累积影响在专用设备、试剂和实验室耗材的采购方面最为显着，这些产品通常透过国际供应商采购。进口设备零件和某些特种化学品的关税增加，推高了进行高解析度结构分析和大规模筛检的实验室的资本支出预期。由于各机构需要重新评估供应商合约以降低成本波动，这可能导致采购时间延长和计划进度延迟。

此外，关税将影响将临床前和早期临床工作外包给美国境外受託研究机构(CRO) 的经济效益。先前依赖跨境供应链韧性的机构正在重新考虑近岸外包和双重采购策略，以维持业务连续性。在跨国合作中，关税引发的价格调整可能会改变许可和共同开发契约的谈判动态，合作伙伴会寻求分担或抵消增加的成本。重要的是，这些变化将促使投资于关键试剂的国内生产以及对替代供应商的检验。这将增强长期韧性，但也需要在短期内重新分配资本和营运资源。总而言之，关税环境凸显了在推进 GPCR 专案时进行策略采购规划和基于情境的财务建模的必要性。

基于全面细分的洞察分析，涵盖受体生物学、临床应用、治疗重点领域和最终用户角色，以支援策略优先排序。

严谨的细分框架揭示了每个受体类别、治疗适应症、开髮用途和最终用户的独特机会和风险特征。基于受体类别，研究领域涵盖A类视紫质受体、B类促胰液素胰泌素、C类代谢型麸胺酸受体、F类捲曲/味觉2受体、孤儿受体。在A类视紫质受体下又包含多个亚类，例如胺基酸受体、趋化素受体、脂质受体、单胺受体、视蛋白受体和胜肽受体，每种亚类都具有其独特的配体结合特性和生物学意义。基于治疗领域，研究活动涵盖心血管疾病、中枢神经系统疾病、胃肠道疾病、发炎、代谢性疾病、肿瘤、疼痛管理和呼吸系统疾病。肿瘤领域的研究进一步细分为乳癌、大肠癌、白血病、肺癌和摄护腺癌，每种癌症都反映了其独特的机制和转化途径。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 冷冻电镜（cryo-EM）引导的基于结构的GPCR靶点药物发现进展
  • 选择性调节GPCR讯号路径的偏向性促效剂的出现
  • 辨识并发现孤儿GPCR的治疗潜力，以及消除孤儿GPCR孤儿状态的努力
  • 开发靶向GPCR的抗体疗法以提高特异性和疗效
  • 人工智慧和机器学习在GPCR配体发现的应用
  • 变构调变器设计的进展可用于微调GPCR受体结构
  • 利用GPCR异源二聚化进行新型药物标靶化与通路偏差
  • 整合光药理方法以实现GPCR活性的时空调控
  • 利用奈米载体进行组织特异性靶向GPCR药物递送的最新进展

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 依受体类别分類的G蛋白偶联受体市场

  • A类视紫质
    • 胺基酸受体
    • 趋化素受体
    • 脂质受体
    • 单胺受体
    • 视蛋白受体
    • 胜肽受体
  • B类胰泌素
  • C类代谢型麸胺酸
  • F级 薯条/口味2
  • 孤儿受体

9. 按治疗领域分類的G蛋白偶联受体市场

  • 心血管疾病
  • 中枢神经系统疾病
  • 消化系统疾病
  • 发炎
  • 代谢性疾病
  • 肿瘤学
    • 乳癌
    • 大肠直肠癌
    • 白血病
    • 肺癌
    • 摄护腺癌
  • 疼痛管理
  • 呼吸系统疾病

第十章 G蛋白偶联受体市场依应用领域划分

  • 临床试验
    • I期试验
    • 第二阶段
    • 第三阶段
  • 诊断
  • 药物发现
  • 临床前开发

第十一章 依最终用户分類的G蛋白偶联受体市场

  • 学术研究机构
  • CRO（受託研究机构）
  • 诊断实验室
  • 製药和生物技术公司

12. 按地区分類的G蛋白偶联受体市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

13. G蛋白偶联受体市场（依组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

14. 各国G蛋白偶联受体市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • F. Hoffmann-La Roche Ltd.
    • Novartis AG
    • Pfizer Inc.
    • Merck & Co., Inc.
    • Johnson & Johnson
    • AstraZeneca PLC
    • Sanofi SA
    • Bristol-Myers Squibb Company
    • GlaxoSmithKline plc
    • AbbVie Inc.
Product Code: MRR-521BAA36EDBA

The G-Protein Coupled Receptors Market is projected to grow by USD 5.80 billion at a CAGR of 6.46% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 3.51 billion
Estimated Year [2025] USD 3.74 billion
Forecast Year [2032] USD 5.80 billion
CAGR (%) 6.46%

A clear and authoritative introduction to GPCR science and commercialization that situates recent technological breakthroughs within therapeutic and translational contexts

G-protein coupled receptors (GPCRs) occupy a central position in cell signaling and therapeutic innovation, representing one of the most pharmacologically tractable families of membrane proteins. Over the past two decades, technological advances such as high-resolution structural biology, cryo-electron microscopy, and integrative computational modeling have reshaped our ability to interrogate receptor conformations, ligand binding modes, and signaling bias. These scientific breakthroughs have translated into a diversified pipeline of small molecules, peptides, biologics, and modality-agnostic discovery platforms that increasingly target previously intractable receptor subtypes.

In addition, the maturation of translational tools-ranging from chemoproteomics to advanced imaging and human cellular models-has strengthened the bridge between target validation and clinical development. Consequently, stakeholders across pharma, biotechnology, academic institutions, and contract research organizations are prioritizing GPCR portfolios that promise differentiated efficacy, improved safety profiles, and novel mechanisms of action. As a result, stakeholders are recalibrating investment theses, collaboration models, and go-to-market strategies to capture opportunities spanning traditional therapeutic areas and emerging indications.

How converging structural biology, computational design, and modality innovation are redefining GPCR-targeted discovery and reshaping collaboration models across the sector

The GPCR landscape is undergoing transformative shifts driven by converging scientific, technological, and business model innovations. Structural determination methods, particularly cryo-electron microscopy and advanced X-ray crystallography, now enable high-resolution snapshots of GPCR-ligand complexes, which in turn accelerate structure-based drug design and rational optimization of lead compounds. Meanwhile, the growing understanding of biased agonism and allosteric modulation has expanded the therapeutic design space, enabling more selective modulation of downstream signaling pathways and potentially reducing off-target effects.

Concurrently, the integration of artificial intelligence and machine learning into ligand design and virtual screening workflows is improving hit identification efficiency and enabling the rapid exploration of chemical space. At the same time, modality diversification-such as peptide therapeutics, antibody-based GPCR targeting, and intracellular delivery approaches-broadens the ways in which receptors can be selectively engaged. Commercially, these technological shifts catalyze new partnership structures between biotechs and large pharmaceutical companies, and they encourage vertical collaboration with specialized contract research organizations and academic centers that house unique assay platforms and patient-derived models. As these trends continue, competitive advantage will increasingly accrue to organizations that combine deep mechanistic insight with agile translational capabilities.

Assessing how tariff-induced supply chain adjustments and procurement volatility are reshaping operational strategies for GPCR research and development across stakeholder groups

Policy changes in 2025 relating to United States tariffs have introduced ripples that affect supply chains, cost structures, and sourcing strategies relevant to GPCR research and development. The cumulative impact is most visible in the procurement of specialized equipment, reagents, and laboratory consumables that are often sourced through international suppliers. Increased duties on imported instrumentation components and certain specialty chemicals elevate capital expenditure estimates for laboratories undertaking high-resolution structural studies or large-scale screening campaigns. In turn, project timelines can be extended as procurement windows lengthen and institutions reassess vendor agreements to mitigate cost volatility.

Moreover, tariffs influence the economics of outsourcing preclinical and early clinical work to contract research organizations located outside the United States. Organizations that previously relied on cross-border supply resilience are now reconsidering nearshoring or dual-sourcing strategies to maintain continuity. For multinational collaborations, tariff-driven price adjustments may alter the negotiating dynamics of licensing deals and joint development agreements, with partners seeking to share or offset incremental costs. Importantly, these shifts encourage investment in domestic manufacturing of key reagents and in the validation of alternative suppliers, which can strengthen long-term resilience but require short-term capital and operational reallocation. Overall, the tariff environment underscores the need for strategic procurement planning and scenario-based financial modeling when advancing GPCR programs.

Comprehensive segmentation-driven insights that map receptor biology, clinical applications, therapeutic focus areas, and end-user roles to inform strategic prioritization

A rigorous segmentation framework reveals differentiated opportunity and risk profiles across receptor classes, therapeutic indications, development applications, and end users. Based on receptor class, the landscape encompasses Class A Rhodopsin, Class B Secretin, Class C Metabotropic Glutamate, Class F Frizzled/Taste 2, and orphan receptors; within Class A Rhodopsin, subcategories include amino acid receptors, chemokine receptors, lipid receptors, monoamine receptors, opsin receptors, and peptide receptors, each presenting unique ligandability and biological implications. Based on therapeutic area, activities span cardiovascular diseases, central nervous system disorders, gastrointestinal disorders, inflammation, metabolic disorders, oncology, pain management, and respiratory disorders; oncology-focused work further subdivides into breast cancer, colorectal cancer, leukemia, lung cancer, and prostate cancer, reflecting distinct mechanisms and translational pathways.

Based on application, the ecosystem includes clinical trials, diagnostics, drug discovery, and preclinical development, with clinical trials progressing through Phase I, Phase II, and Phase III pathways that carry different evidentiary and operational demands. Based on end user, the market serves academic and research institutes, contract research organizations, diagnostic laboratories, and pharmaceutical and biotech companies, each of which plays discrete roles-from basic target discovery to late-stage development and commercialization. Taken together, this segmentation highlights that strategic priorities and resource allocations should be tailored to receptor biology, therapeutic objectives, and the maturity of the application pipeline, while recognizing that cross-segment collaborations frequently accelerate translational progress.

Regional strategic considerations that reconcile scientific capacity, regulatory diversity, and commercial pathways to optimize global GPCR program deployment

Regional dynamics shape investment patterns, regulatory expectations, and operational footprints that influence GPCR-focused programs. In the Americas, robust private investment, a dense network of biopharma companies, and leading academic centers sustain high levels of translational activity, while regulatory frameworks continue to evolve in ways that prioritize expedited pathways for high-need therapies. In Europe, Middle East & Africa, research strength is distributed across academic hubs and specialized biotech clusters, with regulatory diversity prompting region-specific clinical strategies and partnership models. The Asia-Pacific region combines rapidly expanding R&D capacity with significant manufacturing capabilities and a growing presence of clinical trial sites, making it an increasingly important node for both early-stage discovery and large-scale development activities.

These geographic distinctions inform decisions about where to site key operations, how to structure global development plans, and which regional partnerships to pursue. For example, proximity to specialized assay platforms or patient populations may favor localized collaborations, whereas certain regulatory incentives or cost efficiencies can justify centralized development functions. Thus, effective regional strategies require a granular understanding of local ecosystems, talent pools, reimbursement landscapes, and regulatory pathways, and they often benefit from flexible models that balance global coordination with local execution.

How the interplay among pharmaceutical champions, innovative biotechs, academic pioneers, and specialized service providers is shaping competitive advantage in GPCR development

Leading organizations active in GPCR science and development span large pharmaceutical companies, innovative biotech firms, academic centers, and specialized service providers. Established pharmaceutical companies continue to anchor late-stage development and commercialization through deep clinical experience and global regulatory expertise, while nimble biotech companies advance novel modalities, first-in-class targets, and specialized platform technologies. Academic institutions and public research centers remain critical sources of mechanistic insight and early target validation, often generating the translational science that fuels spinouts and licensing opportunities.

Contract research organizations and diagnostic laboratories provide essential infrastructure for assay development, preclinical testing, and clinical trial execution, enabling sponsors to scale programs rapidly without extending fixed capital commitments. In parallel, a growing cohort of technology providers-focusing on AI-driven discovery, high-throughput screening, single-cell functional assays, and advanced structural biology platforms-are creating complementary capabilities that accelerate hit-to-lead cycles. Strategic partnerships between these actors frequently combine proprietary science with operational scale, and competitive differentiation increasingly derives from integrated value chains that link target biology to clinical execution.

Practical, high-impact recommendations for leaders to accelerate GPCR innovation, shore up operational resilience, and align partnerships with translational priorities

Industry leaders should adopt a set of pragmatic, actionable measures to capitalize on scientific momentum while mitigating operational risks. First, prioritize investment in technologies that materially shorten the translational timeline, such as structure-enabled design, advanced biophysical characterization, and AI-augmented ligand discovery, because these capabilities yield higher confidence at earlier decision points. Second, diversify supplier networks and cultivate nearshore partnerships to reduce vulnerability to supply chain disruptions and tariff-driven cost pressures, while concurrently validating alternative reagents and service providers to maintain experimental continuity.

Third, design modular collaboration frameworks that enable dynamic partnerships with academic labs, biotechs, and CROs, aligning incentives through milestone-based agreements and shared data architectures. Fourth, emphasize translational robustness by incorporating human-relevant models, orthogonal validation methods, and early biomarker strategies that de-risk clinical hypotheses. Fifth, develop portfolio governance that balances high-risk, high-reward targets such as orphan receptors with more de-risked programs grounded in validated receptor classes and therapeutic areas. Taken together, these measures support resilient pipelines that can adapt to scientific advances and policy shifts without sacrificing strategic focus.

Transparent and rigorous research methodology combining expert interviews, literature synthesis, structural and clinical data analysis, and scenario-based validation

This research synthesizes multiple complementary methodologies to deliver robust, reproducible findings. Primary information was gathered through structured interviews with domain experts, including academic investigators, clinical leads, and industry R&D executives, which provided qualitative insight into scientific priorities and translational challenges. Secondary research integrated publicly available scientific literature, peer-reviewed publications, patent filings, regulatory filings, and clinical trial registries to map technological trajectories and clinical progress. In addition, analysis of scientific databases and repositories enabled objective assessment of structural biology milestones and modality diversification.

Analytical techniques included thematic synthesis of expert inputs, cross-validation of findings against independent data sources, and scenario analysis to explore operational and policy contingencies such as tariff impacts. Where appropriate, methodological safeguards-such as triangulation across data types and blinded expert review-were applied to reduce bias and improve the reliability of conclusions. The resulting approach emphasizes transparency in assumptions, traceability of evidence, and a clear linkage between scientific findings and practical business implications, thereby facilitating evidence-based decision-making.

A concise and action-oriented conclusion that synthesizes scientific advances, operational realities, and strategic imperatives for sustained GPCR program success

In conclusion, the GPCR domain remains a fertile ground for therapeutic innovation, driven by advances in structural biology, computational design, and a richer understanding of signaling complexity. These developments expand the repertoire of actionable targets and enable increasingly selective therapeutics across a broad spectrum of indications, from central nervous system disorders to oncology and metabolic disease. At the same time, evolving policy environments and supply chain dynamics introduce operational considerations that demand strategic planning and adaptive partnerships.

Looking ahead, success will favor organizations that integrate mechanistic rigor with translational agility: those that invest in enabling technologies, diversify operational dependencies, and design collaborative models that align scientific discovery with clinical execution. By adopting the strategic recommendations outlined here and grounding decisions in validated evidence, stakeholders can enhance the probability of clinical and commercial success while navigating the practical challenges of a rapidly evolving landscape.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Advancements in cryo-EM guided structure-based drug design for GPCR targets
  • 5.2. Emergence of biased agonists to selectively modulate GPCR signaling pathways
  • 5.3. Identification and therapeutic exploration of orphan GPCR deorphanization efforts
  • 5.4. Development of GPCR-targeted antibody therapies for enhanced specificity and efficacy
  • 5.5. Application of artificial intelligence and machine learning to GPCR ligand discovery
  • 5.6. Progress in allosteric modulator design to fine-tune GPCR receptor conformations
  • 5.7. Exploitation of GPCR heteromerization for novel drug targeting and pathway biasing
  • 5.8. Integration of photopharmacology approaches to achieve spatiotemporal control of GPCR activity
  • 5.9. Advances in GPCR-targeted drug delivery using nanocarriers for tissue-specific engagement

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. G-Protein Coupled Receptors Market, by Receptor Class

  • 8.1. Class A Rhodopsin
    • 8.1.1. Amino Acid Receptors
    • 8.1.2. Chemokine Receptors
    • 8.1.3. Lipid Receptors
    • 8.1.4. Monoamine Receptors
    • 8.1.5. Opsin Receptors
    • 8.1.6. Peptide Receptors
  • 8.2. Class B Secretin
  • 8.3. Class C Metabotropic Glutamate
  • 8.4. Class F Frizzled/Taste 2
  • 8.5. Orphan Receptors

9. G-Protein Coupled Receptors Market, by Therapeutic Area

  • 9.1. Cardiovascular Diseases
  • 9.2. Cns Disorders
  • 9.3. Gastrointestinal Disorders
  • 9.4. Inflammation
  • 9.5. Metabolic Disorders
  • 9.6. Oncology
    • 9.6.1. Breast Cancer
    • 9.6.2. Colorectal Cancer
    • 9.6.3. Leukemia
    • 9.6.4. Lung Cancer
    • 9.6.5. Prostate Cancer
  • 9.7. Pain Management
  • 9.8. Respiratory Disorders

10. G-Protein Coupled Receptors Market, by Application

  • 10.1. Clinical Trials
    • 10.1.1. Phase I
    • 10.1.2. Phase II
    • 10.1.3. Phase III
  • 10.2. Diagnostics
  • 10.3. Drug Discovery
  • 10.4. Preclinical Development

11. G-Protein Coupled Receptors Market, by End User

  • 11.1. Academic And Research Institutes
  • 11.2. Contract Research Organizations
  • 11.3. Diagnostic Laboratories
  • 11.4. Pharmaceutical And Biotech Companies

12. G-Protein Coupled Receptors Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. G-Protein Coupled Receptors Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. G-Protein Coupled Receptors Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. F. Hoffmann-La Roche Ltd.
    • 15.3.2. Novartis AG
    • 15.3.3. Pfizer Inc.
    • 15.3.4. Merck & Co., Inc.
    • 15.3.5. Johnson & Johnson
    • 15.3.6. AstraZeneca PLC
    • 15.3.7. Sanofi S.A.
    • 15.3.8. Bristol-Myers Squibb Company
    • 15.3.9. GlaxoSmithKline plc
    • 15.3.10. AbbVie Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY RECEPTOR CLASS, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY RECEPTOR CLASS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. G-PROTEIN COUPLED RECEPTORS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. G-PROTEIN COUPLED RECEPTORS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. G-PROTEIN COUPLED RECEPTORS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY RECEPTOR CLASS, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY RECEPTOR CLASS, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY CLASS A RHODOPSIN, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY CLASS A RHODOPSIN, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY CLASS A RHODOPSIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY CLASS A RHODOPSIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY CLASS A RHODOPSIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY CLASS A RHODOPSIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY CLASS A RHODOPSIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY CLASS A RHODOPSIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY AMINO ACID RECEPTORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY AMINO ACID RECEPTORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY AMINO ACID RECEPTORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY AMINO ACID RECEPTORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY AMINO ACID RECEPTORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY AMINO ACID RECEPTORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY CHEMOKINE RECEPTORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY CHEMOKINE RECEPTORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY CHEMOKINE RECEPTORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY CHEMOKINE RECEPTORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY CHEMOKINE RECEPTORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY CHEMOKINE RECEPTORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY LIPID RECEPTORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY LIPID RECEPTORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY LIPID RECEPTORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY LIPID RECEPTORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY LIPID RECEPTORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY LIPID RECEPTORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY MONOAMINE RECEPTORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY MONOAMINE RECEPTORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY MONOAMINE RECEPTORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY MONOAMINE RECEPTORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY MONOAMINE RECEPTORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY MONOAMINE RECEPTORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY OPSIN RECEPTORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY OPSIN RECEPTORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY OPSIN RECEPTORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY OPSIN RECEPTORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY OPSIN RECEPTORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY OPSIN RECEPTORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY PEPTIDE RECEPTORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY PEPTIDE RECEPTORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY PEPTIDE RECEPTORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY PEPTIDE RECEPTORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY PEPTIDE RECEPTORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY PEPTIDE RECEPTORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY CLASS B SECRETIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY CLASS B SECRETIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY CLASS B SECRETIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY CLASS B SECRETIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY CLASS B SECRETIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY CLASS B SECRETIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY CLASS C METABOTROPIC GLUTAMATE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY CLASS C METABOTROPIC GLUTAMATE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY CLASS C METABOTROPIC GLUTAMATE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY CLASS C METABOTROPIC GLUTAMATE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY CLASS C METABOTROPIC GLUTAMATE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY CLASS C METABOTROPIC GLUTAMATE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY CLASS F FRIZZLED/TASTE 2, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY CLASS F FRIZZLED/TASTE 2, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY CLASS F FRIZZLED/TASTE 2, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY CLASS F FRIZZLED/TASTE 2, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY CLASS F FRIZZLED/TASTE 2, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY CLASS F FRIZZLED/TASTE 2, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY ORPHAN RECEPTORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY ORPHAN RECEPTORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY ORPHAN RECEPTORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY ORPHAN RECEPTORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY ORPHAN RECEPTORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY ORPHAN RECEPTORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY CNS DISORDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY CNS DISORDERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY CNS DISORDERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY CNS DISORDERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY CNS DISORDERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY CNS DISORDERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY GASTROINTESTINAL DISORDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY GASTROINTESTINAL DISORDERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY GASTROINTESTINAL DISORDERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY GASTROINTESTINAL DISORDERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY GASTROINTESTINAL DISORDERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY GASTROINTESTINAL DISORDERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY INFLAMMATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY INFLAMMATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY INFLAMMATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY INFLAMMATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY INFLAMMATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY INFLAMMATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY METABOLIC DISORDERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY METABOLIC DISORDERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY METABOLIC DISORDERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY METABOLIC DISORDERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY ONCOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY ONCOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY BREAST CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY BREAST CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY BREAST CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY COLORECTAL CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY COLORECTAL CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY COLORECTAL CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY COLORECTAL CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY LEUKEMIA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY LEUKEMIA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY LEUKEMIA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY LEUKEMIA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY LEUKEMIA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY LEUKEMIA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY LUNG CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY LUNG CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY LUNG CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY PROSTATE CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY PROSTATE CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY PROSTATE CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY PROSTATE CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY PAIN MANAGEMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY PAIN MANAGEMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY PAIN MANAGEMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY PAIN MANAGEMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY PAIN MANAGEMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY PAIN MANAGEMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY RESPIRATORY DISORDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY RESPIRATORY DISORDERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY RESPIRATORY DISORDERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY RESPIRATORY DISORDERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY RESPIRATORY DISORDERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY RESPIRATORY DISORDERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY CLINICAL TRIALS, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY CLINICAL TRIALS, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY CLINICAL TRIALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY CLINICAL TRIALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY CLINICAL TRIALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY CLINICAL TRIALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY CLINICAL TRIALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY CLINICAL TRIALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY PHASE I, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY PHASE I, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY PHASE I, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY PHASE I, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY PHASE I, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY PHASE I, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY PHASE II, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY PHASE II, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY PHASE II, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY PHASE II, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY PHASE II, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY PHASE II, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY PHASE III, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY PHASE III, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY PHASE III, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY PHASE III, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY PHASE III, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY PHASE III, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY DIAGNOSTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY DIAGNOSTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY DIAGNOSTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY DIAGNOSTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY DRUG DISCOVERY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY DRUG DISCOVERY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY DRUG DISCOVERY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY DRUG DISCOVERY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY DRUG DISCOVERY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY DRUG DISCOVERY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY PRECLINICAL DEVELOPMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY PRECLINICAL DEVELOPMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY PRECLINICAL DEVELOPMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY PRECLINICAL DEVELOPMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY PRECLINICAL DEVELOPMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY PRECLINICAL DEVELOPMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY PHARMACEUTICAL AND BIOTECH COMPANIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY PHARMACEUTICAL AND BIOTECH COMPANIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY PHARMACEUTICAL AND BIOTECH COMPANIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY PHARMACEUTICAL AND BIOTECH COMPANIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY PHARMACEUTICAL AND BIOTECH COMPANIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY PHARMACEUTICAL AND BIOTECH COMPANIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 231. AMERICAS G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 232. AMERICAS G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 233. AMERICAS G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY RECEPTOR CLASS, 2018-2024 (USD MILLION)
  • TABLE 234. AMERICAS G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY RECEPTOR CLASS, 2025-2032 (USD MILLION)
  • TABLE 235. AMERICAS G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY CLASS A RHODOPSIN, 2018-2024 (USD MILLION)
  • TABLE 236. AMERICAS G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY CLASS A RHODOPSIN, 2025-2032 (USD MILLION)
  • TABLE 237. AMERICAS G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 238. AMERICAS G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 239. AMERICAS G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 240. AMERICAS G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 241. AMERICAS G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 242. AMERICAS G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 243. AMERICAS G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY CLINICAL TRIALS, 2018-2024 (USD MILLION)
  • TABLE 244. AMERICAS G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY CLINICAL TRIALS, 2025-2032 (USD MILLION)
  • TABLE 245. AMERICAS G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 246. AMERICAS G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 247. NORTH AMERICA G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 248. NORTH AMERICA G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 249. NORTH AMERICA G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY RECEPTOR CLASS, 2018-2024 (USD MILLION)
  • TABLE 250. NORTH AMERICA G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY RECEPTOR CLASS, 2025-2032 (USD MILLION)
  • TABLE 251. NORTH AMERICA G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY CLASS A RHODOPSIN, 2018-2024 (USD MILLION)
  • TABLE 252. NORTH AMERICA G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY CLASS A RHODOPSIN, 2025-2032 (USD MILLION)
  • TABLE 253. NORTH AMERICA G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 254. NORTH AMERICA G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 255. NORTH AMERICA G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 256. NORTH AMERICA G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 257. NORTH AMERICA G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 258. NORTH AMERICA G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 259. NORTH AMERICA G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY CLINICAL TRIALS, 2018-2024 (USD MILLION)
  • TABLE 260. NORTH AMERICA G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY CLINICAL TRIALS, 2025-2032 (USD MILLION)
  • TABLE 261. NORTH AMERICA G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 262. NORTH AMERICA G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 263. LATIN AMERICA G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 264. LATIN AMERICA G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 265. LATIN AMERICA G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY RECEPTOR CLASS, 2018-2024 (USD MILLION)
  • TABLE 266. LATIN AMERICA G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY RECEPTOR CLASS, 2025-2032 (USD MILLION)
  • TABLE 267. LATIN AMERICA G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY CLASS A RHODOPSIN, 2018-2024 (USD MILLION)
  • TABLE 268. LATIN AMERICA G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY CLASS A RHODOPSIN, 2025-2032 (USD MILLION)
  • TABLE 269. LATIN AMERICA G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 270. LATIN AMERICA G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 271. LATIN AMERICA G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 272. LATIN AMERICA G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 273. LATIN AMERICA G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 274. LATIN AMERICA G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 275. LATIN AMERICA G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY CLINICAL TRIALS, 2018-2024 (USD MILLION)
  • TABLE 276. LATIN AMERICA G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY CLINICAL TRIALS, 2025-2032 (USD MILLION)
  • TABLE 277. LATIN AMERICA G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 278. LATIN AMERICA G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 279. EUROPE, MIDDLE EAST & AFRICA G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 280. EUROPE, MIDDLE EAST & AFRICA G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 281. EUROPE, MIDDLE EAST & AFRICA G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY RECEPTOR CLASS, 2018-2024 (USD MILLION)
  • TABLE 282. EUROPE, MIDDLE EAST & AFRICA G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY RECEPTOR CLASS, 2025-2032 (USD MILLION)
  • TABLE 283. EUROPE, MIDDLE EAST & AFRICA G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY CLASS A RHODOPSIN, 2018-2024 (USD MILLION)
  • TABLE 284. EUROPE, MIDDLE EAST & AFRICA G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY CLASS A RHODOPSIN, 2025-2032 (USD MILLION)
  • TABLE 285. EUROPE, MIDDLE EAST & AFRICA G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 286. EUROPE, MIDDLE EAST & AFRICA G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 287. EUROPE, MIDDLE EAST & AFRICA G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 288. EUROPE, MIDDLE EAST & AFRICA G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 289. EUROPE, MIDDLE EAST & AFRICA G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 290. EUROPE, MIDDLE EAST & AFRICA G-PROTEIN COUPLED RECEPTORS MARKET